Nureca Share Price Today (NURECA)
Today’s Nureca Stock Read
Nureca is trading up 0.71% at ₹240.3. With a market cap of ₹229.86 Cr, it trades at a P/E of 108.46. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
Nureca is trading up 0.71% at ₹240.3. With a market cap of ₹229.86 Cr, it trades at a P/E of 108.46. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
Nureca Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Nureca Limited, framed against the sector median so the premium or discount is obvious at a glance.
Nureca Limited trades at a P/E of 108.46× and P/B of 1.25×.
Valuation
Profitability
Growth
Financial Health
Nureca Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Nureca Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Nureca Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Nureca Limited, switchable between annual and quarterly views, consolidated or standalone.
Nureca Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹229.86 Cr and reported EPS of ₹2.10.
| Period | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue from Operations | 213 | 256 | 111 | 92 | 110 | 147 |
| Other Income | 3 | 8 | 7 | 11 | 12 | 8 |
| Total Income | 216 | 263 | 118 | 102 | 122 | 155 |
| Cost of Goods Sold (COGS) | 99 | 133 | 76 | 61 | 68 | 93 |
| Gross Profit | 114 | 123 | 36 | 31 | 42 | 54 |
| +Operating Expenses | 52 | 67 | 51 | 42 | 49 | 54 |
| EBITDA | 62 | 56 | -15 | -10 | -8 | 0 |
| +Non-Operating Expenses | 2 | 2 | 3 | 3 | 4 | 3 |
| Profit Before Tax (PBT) | 62 | 61 | -11 | -3 | 1 | 5 |
| +Tax Expense | 16 | 16 | -2 | -1 | 0 | 3 |
| Profit/Loss from Discontinued Ops | — | — | — | — | — | 0 |
| Total Profit for Period | 46 | 45 | -8 | -2 | 1 | 2 |
| Net Profit (Owner's PAT) | 46 | 45 | -8 | -2 | 1 | 2 |
| Earnings Per Share (EPS) | 46.37 | 44.96 | -8.25 | -1.79 | 0.85 | 2.18 |
| Diluted Shares Outstanding (Nos.) | 1 | 1 | 1 | 1 | 1 | 1 |
| +Additional Disclosures | 253 | 335 | 205 | 166 | 189 | 243 |
| Sales Growth % | — | 19.72 | -56.44 | -17.42 | 19.29 | 34.02 |
| YoY Sales Growth % | — | 19.72 | -56.44 | -17.42 | 19.29 | 34.02 |
| Material Cost % | — | — | 3 | 11 | 10 | 19 |
| Employee Cost % | 2 | 4 | 14 | 13 | 14 | 12 |
| Other Cost % | 22 | 23 | 31 | 32 | 31 | 25 |
| OPM % | 29 | 22 | -13 | -11 | -7 | 0 |
| Tax % | 26 | 26 | 23 | 29 | 37 | 58 |
| Profit Growth % | — | -3.05 | -118.35 | 78.25 | 147.16 | 145.86 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| +Additional Fields | 61 | 54 | -17 | -13 | -10 | -2 |
Nureca segment analysis: revenue and profit mix.
Disclosed business segments at Nureca with their share of revenue and profit, switchable between consolidated and standalone reporting.
Nureca discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Nureca Limited.
Our AI distills the core fundamental drivers supporting Nureca Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
What you're getting.
No strengths or opportunities on record.
What can break it.
No weaknesses or threats on record.
What would change my mind.
Trim if P/E re-rates above 141. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Nureca Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Nureca Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
Nureca Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Nureca Limited — derived from the live tape, not yesterday's close.
Nureca Limited last traded at ₹240.3 with an intraday range of ₹236.3–₹242 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹240.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 254.17 | +13.87 | +5.77% |
| R3 | 248.47 | +8.17 | +3.40% |
| R2 | 245.23 | +4.93 | +2.05% |
| R1 | 242.77 | +2.47 | +1.03% |
| PIVOT | 239.53 | -0.77 | -0.32% |
| CURRENT | 240.30 | — | — |
| S1 | 225.67 | -14.63 | -6.09% |
| S2 | 231.37 | -8.93 | -3.72% |
| S3 | 233.83 | -6.47 | -2.69% |
| S4 | 237.07 | -3.23 | -1.35% |
NURECA is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: 236.3 ~ 240
Trading Inside opening range
Nureca Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Nureca Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Nureca Limited stood at 51.0% of traded volume, against a 20-day average of 59.6%.
Nureca announcements: results, concalls, ratings, M&A.
Filings Nureca sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Nureca files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 58 documents below.
Press Release
Nureca Limited has informed the Exchange regarding a press release dated Jun 20, 2026, titled "Dr Trust 360 Crosses 2.4 Million Users;Launches…
Updates
Nureca Limited has informed the Exchange regarding 'Intimation regarding no change in the aggregate shareholding of the Promoter and Promoter Group…
Updates
Nureca Limited has informed the Exchange regarding 'Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of…
Updates
Nureca Limited has informed the Exchange regarding 'Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of…
Investor decks & rating reports.
Nureca dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Nureca has declared, sequenced by announce and record date.
Nureca corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Nureca Limited: business, sector, key facts.
What Nureca Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Nureca Limited operates in the Medical Equipment & Supplies industry under the Healthcare sector, listed as NSE: NURECA, BSE: 543264.
Nureca Limited is an Indian company specializing in the manufacturing and distribution of a wide range of home healthcare and wellness products. Their business model focuses on providing consumers with accessible and affordable solutions for various health and wellness needs, spanning across several product categories.
A significant portion of their product portfolio centers around chronic disease management. This includes essential medical devices such as nebulizers for respiratory health, blood pressure monitors for cardiovascular health, pulse oximeters for blood oxygen monitoring, glucose meters for diabetes management, and thermometers for temperature checks. They also offer connected health products, integrating technology to enhance the user experience and data tracking.
Beyond chronic disease management, Nureca offers a diverse range of orthopedic products aimed at pain relief, posture correction, and rehabilitation. This includes massagers, pain management devices, posture correctors, and other aids for musculoskeletal health. Furthermore, they provide products for personal care, including humidifiers, steamers, personal scales, and dental care items. Their offerings extend to fitness and wellness with yoga and exercise equipment, fitness trackers, and smart weighing scales.
Nureca also caters to the needs of mothers and babies with a dedicated line of products under their Trumom brand. This includes baby feeding products, carry cots, baby skincare products, and bottle warmers and steamers. In addition to these core product lines, they offer nutritional supplements and weight management products to support overall health and well-being. The company also provides ECG products, bolstering their diagnostic device offerings.
The company's distribution strategy utilizes a multi-channel approach, leveraging the power of e-commerce platforms to reach a broad customer base. They also maintain relationships with distributors and retailers to expand their market reach and ensure wider product availability. Their own websites serve as additional avenues for direct consumer engagement and sales.
Nureca's brand portfolio includes Dr Trust, Dr Physio, and Trumom, each likely targeting specific market segments within the broader healthcare and wellness landscape. These brands, combined with their diverse product offerings and multi-channel distribution strategy, contribute to their position within the competitive Indian healthcare market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Laxmi Dental (LAXMIDENTL) Share PricePeer
- Poly Medicure (POLYMED) Share PricePeer
- Tarsons Products (TARSONS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Nureca Limited (NURECA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Nureca Limited (NURECA)?
The current share price of Nureca Limited (NURECA) is ₹240.3. Today, the stock has gained by ₹1.70 (0.71%), trading in a range of ₹236.3 to ₹242. The stock opened at ₹237.6 with a trading volume of 7,148 shares.
02Is Nureca Limited stock a good investment for long-term?
Nureca Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹229.86 crores, P/E ratio of 108.46, ROE of 1.11%, and ROCE of -0.90%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Nureca Limited stock?
The 52-week high price of Nureca Limited (NURECA) is ₹343, while the 52-week low is ₹204. Currently trading at ₹240.3, the stock is 26.1% away from its 52-week low and 29.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Nureca Limited stock at the current price?
Whether to buy Nureca Limited stock at ₹240.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 108.46 and P/B ratio of 1.25. Today's performance shows a gain of 0.71%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Nureca Limited and when is the next dividend?
Nureca Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹240.3, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Nureca Limited?
Nureca Limited's key financial metrics include: P/E Ratio: 108.46, P/B Ratio: 1.25, ROE: 1.11%, ROCE: -0.90%, Dividend Yield: 0.00%, EPS: ₹2.10, Book Value: ₹191.38, and Debt-to-Equity: 0.01. The company's market cap stands at ₹229.86 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Nureca Limited stock performing today in the market?
Nureca Limited stock opened at ₹237.6 and is currently trading at ₹240.3, showing a gain of ₹1.70 (0.71%). The intraday high is ₹242 and low is ₹236.3. The trading volume stands at 7,148 shares, indicating moderate market participation today.
08What is the P/E ratio of Nureca Limited and what does it indicate?
Nureca Limited has a Price-to-Earnings (P/E) ratio of 108.46, which means investors are willing to pay ₹108.46 for every ₹1 of earnings. With an EPS of ₹2.10, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Nureca Limited (NURECA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.